StockData
Beam Therapeutics Inc. logo

Beam Therapeutics Inc. (BEAM) stock

BEAMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/304% below fair value
$22.83−1.20 (-4.99%)

Close on Nov 13, 2026Market cap $2.36BP/E –Yield –

Beam Therapeutics cash

Cash and short-term investments held at the end of each period.

Beam Therapeutics's cash was $1.20B at Jun 30, 2026. For fiscal 2025 it was $1.20B, up 41.1% from the year before. The highest annual figure on record is $1.20B in fiscal 2023.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.20B+41.1%
FY2024Dec 31, 2024$850.70M-29.1%
FY2023Dec 31, 2023$1.20B+9.1%
FY2022Dec 31, 2022$1.10B+13.9%
FY2021Dec 31, 2021$965.60M+222.2%
FY2020Dec 31, 2020$299.70M+492.8%
FY2019Dec 31, 2019$50.55M-65.8%
FY2018Dec 31, 2018$147.94M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.20B0.0%
Q1 FY2026Mar 31, 2026$1.20B0.0%
Q4 FY2025Dec 31, 2025$1.20B+41.1%
Q3 FY2025Sep 30, 2025$1.10B+18.8%
Q2 FY2025Jun 30, 2025$1.20B+20.0%
Q1 FY2025Mar 31, 2025$1.20B+9.1%
Q4 FY2024Dec 31, 2024$850.70M-29.1%
Q3 FY2024Sep 30, 2024$925.80M-7.4%
Q2 FY2024Jun 30, 2024$1.00B-9.1%
Q1 FY2024Mar 31, 2024$1.10B0.0%
Q4 FY2023Dec 31, 2023$1.20B+9.1%
Q3 FY2023Sep 30, 2023$1.00B-9.1%
Q2 FY2023Jun 30, 2023$1.10B-8.3%
Q1 FY2023Mar 31, 2023$1.10B-8.3%
Q4 FY2022Dec 31, 2022$1.10B+13.9%
Q3 FY2022Sep 30, 2022$1.10B+17.8%
Q2 FY2022Jun 30, 2022$1.20B+95.0%
Q1 FY2022Mar 31, 2022$1.20B+138.3%
Q4 FY2021Dec 31, 2021$965.60M+222.2%
Q3 FY2021Sep 30, 2021$933.40M+361.6%
Q2 FY2021Jun 30, 2021$615.30M+169.9%
Q1 FY2021Mar 31, 2021$503.50M+98.7%
Q4 FY2020Dec 31, 2020$299.70M+492.8%
Q3 FY2020Sep 30, 2020$202.20M+435.4%
Q2 FY2020Jun 30, 2020$228.00M+502.3%
Q1 FY2020Mar 31, 2020$253.40M+62.3%
Q4 FY2019Dec 31, 2019$50.55M-65.8%
Q3 FY2019Sep 30, 2019$37.76M–
Q2 FY2019Jun 30, 2019$37.85M–
Q1 FY2019Mar 31, 2019$156.14M–
Q4 FY2018Dec 31, 2018$147.94M–

More Beam Therapeutics figures

See a number that looks wrong?